全文获取类型
收费全文 | 59165篇 |
免费 | 3882篇 |
国内免费 | 270篇 |
专业分类
耳鼻咽喉 | 701篇 |
儿科学 | 1471篇 |
妇产科学 | 1367篇 |
基础医学 | 8150篇 |
口腔科学 | 1789篇 |
临床医学 | 6435篇 |
内科学 | 12359篇 |
皮肤病学 | 909篇 |
神经病学 | 5818篇 |
特种医学 | 2140篇 |
外科学 | 7753篇 |
综合类 | 464篇 |
一般理论 | 48篇 |
预防医学 | 4381篇 |
眼科学 | 960篇 |
药学 | 3886篇 |
1篇 | |
中国医学 | 67篇 |
肿瘤学 | 4618篇 |
出版年
2023年 | 344篇 |
2022年 | 679篇 |
2021年 | 1239篇 |
2020年 | 810篇 |
2019年 | 1075篇 |
2018年 | 1311篇 |
2017年 | 1145篇 |
2016年 | 1362篇 |
2015年 | 1408篇 |
2014年 | 1923篇 |
2013年 | 2731篇 |
2012年 | 4132篇 |
2011年 | 4334篇 |
2010年 | 2539篇 |
2009年 | 2323篇 |
2008年 | 3594篇 |
2007年 | 3906篇 |
2006年 | 3544篇 |
2005年 | 3545篇 |
2004年 | 3296篇 |
2003年 | 3089篇 |
2002年 | 2861篇 |
2001年 | 704篇 |
2000年 | 655篇 |
1999年 | 763篇 |
1998年 | 658篇 |
1997年 | 543篇 |
1996年 | 466篇 |
1995年 | 433篇 |
1994年 | 372篇 |
1993年 | 367篇 |
1992年 | 471篇 |
1991年 | 475篇 |
1990年 | 432篇 |
1989年 | 450篇 |
1988年 | 396篇 |
1987年 | 418篇 |
1986年 | 383篇 |
1985年 | 391篇 |
1984年 | 327篇 |
1983年 | 290篇 |
1982年 | 265篇 |
1981年 | 238篇 |
1980年 | 199篇 |
1979年 | 244篇 |
1978年 | 216篇 |
1977年 | 215篇 |
1976年 | 167篇 |
1975年 | 170篇 |
1974年 | 158篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
92.
93.
Andrea von Berg Renate Engelstätter Predrag Minic Miodrag Sréckovic Maria Luz Garcia Garcia Tadeusz Lato Jan H. Vermeulen Stefan Leichtl Stefan Hellbardt Thomas D. Bethke 《Pediatric allergy and immunology》2007,18(5):391-400
Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 microg (ex-actuator; nominal dose 200 microg) vs. budesonide 400 microg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 microg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus spacer) or budesonide 400 microg once daily (via Turbohaler) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 microg once daily and budesonide 400 microg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk. 相似文献
94.
Nan-Fu Chen Yeou-Chih Wang Chiung-Chyi Shen Yee-Jee Jan Wen-Hsien Chen Ching-Hsiang Leu 《Journal of clinical neuroscience》2004,11(5):527-530
We report a case of calcified chronic encapsulated intracerebral haematoma (ICH) in a 29-year-old female who presented with progressive left sided weakness and intermittent seizures since childhood. The preoperative magnetic resonance (MR) imaging of the head initially suggested that a partially thrombosed aneurysm or vascular malformation was present. However, no vascular stain was found on the digital subtraction angiography (DSA) of both the carotid and vertebral arteries. The excised mass was histologically diagnosed as a chronic ICH. We traced the patient's medical history and found that at the age of one she sustained a head injury after a fall. So far, to our knowledge, no case of epilepsy secondary to a calcified chronic encapsulated ICH occurring 28 years after head injury has been reported. Calcified chronic encapsulated ICH concomitant with new bone formation within is even rarer. The possible pathogenesis of this case is discussed. 相似文献
95.
96.
97.
Expression profiling identifies the CRH/CRH-R1 system as a modulator of neurovascular gene activity.
Jan M Deussing Claudia Kühne Benno Pütz Markus Panhuysen Johannes Breu Mary P Stenzel-Poore Florian Holsboer Wolfgang Wurst 《Journal of cerebral blood flow and metabolism》2007,27(8):1476-1495
Corticotropin-releasing hormone receptor type 1 (CRH-R1)-deficient mice display reduced anxiety-like behavior, a chronic corticosterone deficit, and an impaired neuroendocrine stress response caused by disruption of the hypothalamic-pituitary-adrenocortical (HPA) axis. The molecular substrates and pathways of CRH/CRH-R1-dependent signaling mechanisms underlying the behavioral phenotype as well as the consequences of lifelong glucocorticoid deficit remain largely obscure. To dissect involved neuronal circuitries, we performed comparative expression profiling of brains of CRH-R1 mutant and wild-type mice using our custom made MPIP (Max Planck Institute of Psychiatry) 17k cDNA microarray. Microarray analysis yielded 107 genes showing altered expression levels when comparing CRH-R1 knockout mice with wild-type littermates. A significant proportion of differentially expressed genes was related to control of HPA and hypothalamic-pituitary-thyroid (HPT) axes reflecting not only the disturbance of the HPA axis in CRH-R1 mutant mice but also the interplay of both neuroendocrine systems. The spatial analysis of regulated genes revealed a prevalence for genes expressed in the cerebral microvasculature. This phenotype was confirmed by the successful cross-validation of regulated genes in CRH overexpressing mice. Analysis of the cerebral vasculature of CRH-R1 mutant and CRH overexpressing mice revealed alterations of functional rather than structural properties. A direct role of the CRH/CRH-R1 system was supported by demonstrating Crhr1 expression in the adult murine cerebral vasculature. In conclusion, these data suggest a novel, previously unknown role of the CRH/CRH-R1 system in modulating neurovascular gene expression and function. 相似文献
98.
Machado-Joseph disease is a dominantly inherited, multisystem, degenerative disorder that lacks a proven genetic marker. Peripheral nerve conduction-refractory period, sensory evoked potentials, and quantified oculomotor recordings were studied in nine patients affected with this disease to look for a potential physiologic marker. Only the oculomotor measurements of saccade and smooth pursuit gain were consistently abnormal in all patients. Identical eye movement recordings in 12 asymptomatic individuals at risk for Machado-Joseph disease revealed findings typical of affected patients in only 1 individual. Quantified oculomotor studies may contribute to the early confirmation of the disease, primarily in individuals at risk with minor or equivocal neurologic signs. 相似文献
99.
L. Rosenberg M.D. I. T. Jackson D. Sharpe J. Weiss 《European journal of plastic surgery》1987,9(4):158-159
Summary A system which can be used for injection or infiltration of large volumes of fluid is described. This consists of a syringe which fills automatically from a reservoir through an inlet/outlet valve. 相似文献
100.
We have prospectively evaluated the skin changes that occurred in ten patients who were undergoing immunotherapy with interleukin 2 (IL-2) and autologous lymphokine-activated killer cells to treat cancer. Serial skin biopsy specimens were obtained before therapy (baseline), during IL-2 administration, and during IL-2/lymphokine-activated killer cell infusion. All patients developed an eruption that was characterized by macular erythema, with burning and pruritus of the skin. It began after two or three days of IL-2 infusion and was usually localized to the head and neck; it occasionally became generalized (ie, erythroderma). The eruption resolved with desquamation within 48 to 72 hours after cessation of infusion of IL-2. Histologically, the changes were not specific. The only consistent immunohistological finding noted was the presence of DR+/Leu-4+ lymphoid cells surrounding blood vessels in the papillary dermis, with fewer of these cells in the epidermis. There was no difference between the clinical or histological features of the eruption that occurred with IL-2 alone and that which occurred with IL-2 and lymphokine-activated killer cell infusion, suggesting that the cutaneous effects were mediated by IL-2 alone. 相似文献